ARYx Therapeutics, Inc.
ARYX · OTC
9/30/2010 | 6/30/2010 | 3/31/2010 | 12/31/2009 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $1 | $1 | $2 | $3 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1 | $2 | $4 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2 | $3 | $6 | $5 |
| Operating Income | -$2 | -$3 | -$6 | -$5 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | $0 | $0 | $0 | $0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$3 | -$4 | -$6 | -$6 |
| % Margin | – | – | – | – |
| EPS | -0.075 | -0.11 | -0.22 | -0.21 |
| % Growth | 31.7% | 50% | -4.8% | – |
| EPS Diluted | -0.075 | -0.11 | -0.22 | -0.21 |
| Weighted Avg Shares Out | 33 | 33 | 29 | 28 |
| Weighted Avg Shares Out Dil | 33 | 33 | 29 | 28 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$2 | -$3 | -$6 | -$5 |
| % Margin | – | – | – | – |